HER2 Support Group Forums - View Single Post

Rich66 · 02-13-2009, 05:51 PM

I just reread this and was impressed by this portion:

"Preclinically, tesetaxel has demonstrated substantially higher activity against cell lines that were resistant to paclitaxel and docetaxel, since acquired resistance is not mediated by the multidrug-resistant p-glycoprotein.
As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with other taxanes. Moreover, unlike other oral taxanes, nerve damage has not been a prominent side effect of tesetaxel. Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity."

A release appeared today stating:
Feb 13, 2009 (Datamonitor via COMTEX) -- GNTA | Quote | Chart | News | PowerRating -- Genta, a biopharmaceutical company

, has submitted a proposal to the FDA for a randomized clinical trial of tesetaxel, an oral taxane chemotherapy compound, for special protocol assessment.

02-13-2009, 05:51 PM	#2
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	I just reread this and was impressed by this portion: "Preclinically, tesetaxel has demonstrated substantially higher activity against cell lines that were resistant to paclitaxel and docetaxel, since acquired resistance is not mediated by the multidrug-resistant p-glycoprotein. As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with other taxanes. Moreover, unlike other oral taxanes, nerve damage has not been a prominent side effect of tesetaxel. Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity." A release appeared today stating: Feb 13, 2009 (Datamonitor via COMTEX) -- GNTA \| Quote \| Chart \| News \| PowerRating -- Genta, a biopharmaceutical company, has submitted a proposal to the FDA for a randomized clinical trial of tesetaxel, an oral taxane chemotherapy compound, for special protocol assessment.